evobrutinib vs ritlecitinib
Mechanistic comparison of evobrutinib and ritlecitinib based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
5
Shared Targets
38%
Jaccard Similarity
37%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Evidence Comparison
Target Overlap
evobrutinib and ritlecitinib share 5 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.385 means 38% of the combined target set is bound by both compounds. The IDF-weighted score of 0.370 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.